1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
1. A method of treatment of a cognitive disorder, a learning deficit, a memory deficit or dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder (ADHD), schizophrenia, a cognitive or attention deficit related to schizophrenia, AIDS-dementia, senile dementia, senile dementia of the Alzheimer's type, an inflammatory disorder, Crohn's disease, inflammatory bowel disease, or ulcerative colitis, which method comprises
administering to a living animal body in need thereof a therapeutically effective amount of a 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compound represented by Formula I, or a pharmaceutically-acceptable salt thereof,
wherein Ar represents a phenyl group, which phenyl is substituted with methylenedioxy or ethylenedioxy.
2. The method according to claim 1 , wherein said living animal body is a human.
3. The method according to claim 1 , for the treatment of a cognitive disorder, a learning deficit, or a memory deficit or dysfunction.
4. The method according to claim 1 , for the treatment of senile dementia of the Alzheimer's type.
5. The method according to claim 1 , for the treatment of attention deficit or attention deficit hyperactivity disorder (ADHD).
6. The method according to claim 1 , for the treatment of schizophrenia, or a cognitive or attention deficit related to schizophrenia.
7. The method according to claim 1 , for the treatment of an inflammatory disorder, Crohn's disease, inflammatory bowel disease, or ulcerative colitis.
8. The method according to claim 1 , wherein the 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compound is
4-(5-benzo[1,3]dioxol-5-yl)-[,3,4]oxadiazol-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane;
or a pharmaceutically acceptable salt thereof.
9. The method according to claim 1 , wherein the 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compound is 4-(5-benzo[1,3]dioxol-5-yl)-[,3,4]oxadiazol-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane fumaric acid salt.
10. The method according to claim 1 , wherein the 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compound is administered in the dosage range of from 10 to 500 milligrams daily.
11. The method according to claim 1 , wherein the 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compound is administered in the dosage range of from 30 to 100 milligrams daily.